BridgeBio data in ATTR-CM ‘bodes well’ for Alnylam, says BofA

After BridgeBio (BBIO) reported “positive” data from the phase 3 ATTRibute-CM trial evaluating acoramidis in ATTR-CM, or transthyretin amyloidosis cardiomyopathy, BofA said the data that exceeded expectations and showed benefit in all-cause mortality read through positively to Alnylam (ALNY) and “bodes well” for the HELIOS-B readout of vutrisiran in ATTR-CM due in early 2024. The firm, which said BridgeBio’s results reinforce its confidence in vutrisiran’s commercial opportunity in ATTR-CM, maintains a Buy rating and $262 on Alnylam shares.